Cingulate Stock Today
| CING Stock | USD 4.38 0.04 0.92% |
PerformanceSoft
| Odds Of DistressRisky
|
Cingulate is trading at 4.38 as of the 3rd of January 2026. This is a 0.92 percent increase since the beginning of the trading day. The stock's lowest day price was 4.26. Cingulate has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 7th of July 2025 and ending today, the 3rd of January 2026. Click here to learn more.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.76 M outstanding shares of which 347.25 K shares are currently shorted by private and institutional investors with about 2.81 trading days to cover. More on Cingulate
Moving against Cingulate Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cingulate Stock Highlights
| Principal CEO | PharmD PharmD |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Cingulate (CING) is traded on NASDAQ Exchange in USA and employs 13 people. Cingulate is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.33 M. Cingulate conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.76 M outstanding shares of which 347.25 K shares are currently shorted by private and institutional investors with about 2.81 trading days to cover.
Cingulate currently holds about 8.2 M in cash with (18.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.73.
Check Cingulate Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cingulate is $29.33 Million. Almost 94.13 percent of Cingulate outstanding shares are held by general public with 1.5 (percent) owned by insiders and only 4.37 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cingulate Ownership Details
Cingulate Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cingulate market risk premium is the additional return an investor will receive from holding Cingulate long position in a well-diversified portfolio.
| Mean Deviation | 2.92 | |||
| Semi Deviation | 4.05 | |||
| Standard Deviation | 3.73 | |||
| Variance | 13.93 |
Cingulate Stock Against Markets
Cingulate Corporate Management
| Craig Esq | Gen VP | Profile | |
| Thomas Dalton | Head Relations | Profile | |
| Bryan Downey | Chief Officer | Profile | |
| Downey Wade | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.